Role of thromboxane in the generation of allograft arteriosclerosis in chronic rejection.
Häyry
P
P
Transplantation Laboratory, University of Helsinki, Finland.
Mennander
A
A
Paavonen
T
T
Räisänen
A
A
Ustinov
J
J
D000818:Animals; D001011:Aorta / Q000166:cytology / Q000502:physiology / Q000637:transplantation*; D001161:Arteriosclerosis / Q000473:pathology / Q000503:physiopathology*; D001713:Biphenyl Compounds / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D015777:Eicosanoids / Q000096:biosynthesis*; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D006084:Graft Rejection / Q000473:pathology*; D006538:Heptanoic Acids / Q000494:pharmacology; D066298:In Vitro Techniques; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000502:physiology / Q000637:transplantation; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011920:Rats, Inbred WF; D013929:Thromboxane B2 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D001713:Biphenyl Compounds; D015777:Eicosanoids; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D011725:Pyridines; D013929:Thromboxane B2; C060013:vapiprost; C045446:isbogrel